AR009672A1 - Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par - Google Patents
Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica parInfo
- Publication number
- AR009672A1 AR009672A1 ARP970106029A ARP970106029A AR009672A1 AR 009672 A1 AR009672 A1 AR 009672A1 AR P970106029 A ARP970106029 A AR P970106029A AR P970106029 A ARP970106029 A AR P970106029A AR 009672 A1 AR009672 A1 AR 009672A1
- Authority
- AR
- Argentina
- Prior art keywords
- naftil
- trifluorometil
- fenil
- etil
- tetrahydropyridine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 2
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 1
- XLORXPQTDZWKBY-UHFFFAOYSA-N Cl.FC(F)(F)C1=C(C=CC=C1)N1CCC=CC1 Chemical compound Cl.FC(F)(F)C1=C(C=CC=C1)N1CCC=CC1 XLORXPQTDZWKBY-UHFFFAOYSA-N 0.000 abstract 1
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9615904A FR2757543B1 (fr) | 1996-12-23 | 1996-12-23 | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009672A1 true AR009672A1 (es) | 2000-04-26 |
Family
ID=9499043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970106029A AR009672A1 (es) | 1996-12-23 | 1997-12-19 | Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par |
Country Status (38)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
| FR2782082B3 (fr) * | 1998-08-05 | 2000-09-22 | Sanofi Sa | Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose |
| EP2546286B1 (en) | 2010-03-12 | 2019-09-25 | Nippon Shokubai Co., Ltd. | Method for manufacturing a water-absorbing resin |
| US8952155B2 (en) * | 2011-04-15 | 2015-02-10 | Emcure Pharmaceuticals Limited | Rilpivirine process |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2531707A1 (fr) * | 1982-08-16 | 1984-02-17 | Midy Spa | Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques |
| FR2757543B1 (fr) * | 1996-12-23 | 1999-04-02 | Sanofi Sa | Procede pour la cristallisation d'un derive de tetrahydropyridine et formes cristallines ainsi obtenues |
-
1996
- 1996-12-23 FR FR9615904A patent/FR2757543B1/fr not_active Expired - Fee Related
-
1997
- 1997-12-19 AR ARP970106029A patent/AR009672A1/es not_active Application Discontinuation
- 1997-12-22 MY MYPI97006233A patent/MY118015A/en unknown
- 1997-12-22 HR HR970699A patent/HRP970699B1/xx not_active IP Right Cessation
- 1997-12-22 DZ DZ970233A patent/DZ2383A1/xx active
- 1997-12-23 NZ NZ336130A patent/NZ336130A/xx not_active IP Right Cessation
- 1997-12-23 PL PL97334256A patent/PL190494B1/pl not_active IP Right Cessation
- 1997-12-23 CN CN97180863A patent/CN1129580C/zh not_active Expired - Fee Related
- 1997-12-23 AT AT97952986T patent/ATE307802T1/de active
- 1997-12-23 UA UA99063521A patent/UA60324C2/uk unknown
- 1997-12-23 CA CA002275596A patent/CA2275596C/en not_active Expired - Fee Related
- 1997-12-23 DK DK97952986T patent/DK0950050T3/da active
- 1997-12-23 ES ES97952986T patent/ES2251038T3/es not_active Expired - Lifetime
- 1997-12-23 IN IN3761DE1997 patent/IN186976B/en unknown
- 1997-12-23 RU RU99116597/04A patent/RU2192416C2/ru not_active IP Right Cessation
- 1997-12-23 SK SK828-99A patent/SK285088B6/sk not_active IP Right Cessation
- 1997-12-23 IL IL12993897A patent/IL129938A/en not_active IP Right Cessation
- 1997-12-23 KR KR1019997005373A patent/KR100586670B1/ko not_active Expired - Fee Related
- 1997-12-23 AU AU56684/98A patent/AU736697B2/en not_active Ceased
- 1997-12-23 TR TR1999/01363T patent/TR199901363T2/xx unknown
- 1997-12-23 EE EEP199900264A patent/EE04188B1/xx not_active IP Right Cessation
- 1997-12-23 WO PCT/FR1997/002393 patent/WO1998028271A1/fr active IP Right Grant
- 1997-12-23 ZA ZA9711576A patent/ZA9711576B/xx unknown
- 1997-12-23 DE DE69734460T patent/DE69734460T2/de not_active Expired - Lifetime
- 1997-12-23 SI SI9730720T patent/SI0950050T1/sl unknown
- 1997-12-23 JP JP52848198A patent/JP4499188B2/ja not_active Expired - Fee Related
- 1997-12-23 BR BR9714081-3A patent/BR9714081A/pt not_active Application Discontinuation
- 1997-12-23 HU HU0001387A patent/HU227425B1/hu not_active IP Right Cessation
- 1997-12-23 CO CO97074792A patent/CO5070688A1/es unknown
- 1997-12-23 RS YUP-289/99A patent/RS49882B/sr unknown
- 1997-12-23 EP EP97952986A patent/EP0950050B1/fr not_active Expired - Lifetime
- 1997-12-23 EG EG138397A patent/EG21567A/xx active
- 1997-12-23 UY UY24825A patent/UY24825A1/es not_active IP Right Cessation
- 1997-12-23 CZ CZ0229299A patent/CZ296689B6/cs not_active IP Right Cessation
-
1998
- 1998-01-21 TW TW086119629A patent/TW518322B/zh not_active IP Right Cessation
- 1998-03-11 SA SA98180971A patent/SA98180971B1/ar unknown
-
1999
- 1999-06-10 IS IS5076A patent/IS2357B/is unknown
- 1999-06-22 NO NO19993076A patent/NO312364B1/no not_active IP Right Cessation
-
2009
- 2009-05-07 JP JP2009112971A patent/JP2009197022A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP056023A (es) | Métodos para aislar la forma cristalina I de la 5-azacitidina | |
| CO5011099A1 (es) | Formulaciones en polvo en estado cristalino estable | |
| ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| NO954400D0 (no) | Substituerte pyrrolidin-3-yl-alkyl-piperidiner som er anvendbare som tachykininantagonister | |
| DE69904302D1 (de) | Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung | |
| GT199900119A (es) | Jarabe antihistaminico estabilizado. | |
| BRPI0313942C1 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
| ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
| NO20060379L (no) | Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre | |
| AR077416A2 (es) | Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos | |
| CO5280050A1 (es) | Desnaturalizantes para las sales aminas simpaticomimeticas | |
| EA200200510A1 (ru) | 4-карбоксиамино-2-этил-1,2,3,4-тетрагидрохинолин в кристаллической форме как ингибитор сетр | |
| NO20055867L (no) | Meldonium salts, method of their preparation and pharmaceutical composition on their basis | |
| DK0726893T3 (da) | Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma | |
| BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
| UY27410A1 (es) | Formas novedosas crudas cristalinas | |
| MY133445A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives | |
| AR027360A1 (es) | Composicion farmaceutica | |
| ES2046671T3 (es) | Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-tionas. | |
| AR009672A1 (es) | Un metodo para cristalizar clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina, una mezclas de la formas i y de la forma iii de dicho clorhidrato de 1-[2-(2-naftil) etil]-4-(3-trifluorometil-fenil)-1,2,3,6-tetrahidropiridina ; y una composicion farmacéutica par | |
| BRPI0411308A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
| AR030416A1 (es) | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA | |
| CO4700300A1 (es) | Procedimiento para preparar olanzapina | |
| BR0109508A (pt) | Forma ii, cristalina, de cabergolina | |
| AR026209A1 (es) | Compuestos monociclicos basicos con accion nk-2 antagonista, procesos de fabricacion y formulas que los contienen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |